In last trading session, Emergent Biosolutions Inc (NYSE:EBS) saw 0.51 million shares changing hands with its beta currently measuring 1.60. Company’s recent per share price level of $10.18 trading at $0.07 or 0.69% at ring of the bell on the day assigns it a market valuation of $551.59M. That closing price of EBS’s stock is at a discount of -48.33% from its 52-week high price of $15.10 and is indicating a premium of 86.05% from its 52-week low price of $1.42. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.44 million shares which gives us an average trading volume of 1.86 million if we extend that period to 3-months.
For Emergent Biosolutions Inc (EBS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.33. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.64 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Emergent Biosolutions Inc (NYSE:EBS) trade information
Upright in the green during last session for gaining 0.69%, in the last five days EBS remained trading in the green while hitting it’s week-highest on Friday, 11/29/24 when the stock touched $10.18 price level, adding 2.4% to its value on the day. Emergent Biosolutions Inc’s shares saw a change of 324.17% in year-to-date performance and have moved 8.30% in past 5-day. Emergent Biosolutions Inc (NYSE:EBS) showed a performance of 6.04% in past 30-days. Number of shares sold short was 6.81 million shares which calculate 4.42 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 51.5 to the stock, which implies a rise of 80.23% to its current value. Analysts have been projecting 38 as a low price target for the stock while placing it at a high target of 65. It follows that stock’s current price would drop -273.28% in reaching the projected high whereas dropping to the targeted low would mean a loss of -273.28% for stock’s current value.
Emergent Biosolutions Inc (EBS) estimates and forecasts
Statistics highlight that Emergent Biosolutions Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 78.60% of value to its shares in past 6 months, showing an annual growth rate of 79.13% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 5.58% from the last financial year’s standing.
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 259M for the same.
Emergent Biosolutions Inc (NYSE:EBS)’s Major holders
Insiders are in possession of 2.09% of company’s total shares while institution are holding 59.91 percent of that, with stock having share float percentage of 61.19%. Investors also watch the number of corporate investors in a company very closely, which is 59.91% institutions for Emergent Biosolutions Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at EBS for having 3.84 million shares of worth $26.18 million. And as of 2024-06-30, it was holding 7.3551 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 3.67 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.0234 of outstanding shares, having a total worth of $25.0 million.
On the other hand, Schwab Strategic Tr-Schwab Fundamental U.S. Small Company Index ETF and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Aug 31, 2024 , the former fund manager was holding 2.36 shares of worth $23.88 million or 4.36% of the total outstanding shares. The later fund manager was in possession of 1.66 shares on Sep 30, 2024 , making its stake of worth around $16.75 million in the company or a holder of 3.06% of company’s stock.
